Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2017: 3.556

CiteScore 2017: 2.34

SCImago Journal Rank (SJR) 2017: 1.114
Source Normalized Impact per Paper (SNIP) 2017: 1.188

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 43, Issue 10

Issues

Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality

Rainer H. Böger
  • Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Renke Maas
  • Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Friedrich Schulze
  • Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Edzard Schwedhelm
  • Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2011-09-21 | DOI: https://doi.org/10.1515/CCLM.2005.196

Abstract

The endothelium plays a crucial role in the maintenance of vascular tone and structure by releasing the endothelium-derived vasoactive mediator, nitric oxide (NO). NO is formed in healthy vascular endothelium from the amino acid precursor L-arginine. Endothelial dysfunction is caused by various cardiovascular risk factors, metabolic diseases, and systemic or local inflammation. One mechanism that explains the occurrence of endothelial dysfunction is the presence of elevated blood levels of asymmetric dimethylarginine (ADMA) – an L-arginine analogue that inhibits NO formation and thereby can impair vascular function. Accumulating evidence from prospective clinical studies suggests that elevated plasma or serum levels of ADMA are associated with an increased risk of major adverse cardiovascular events. This article gives an updated overview of the currently available literature on ADMA and cardiovascular disease from prospective clinical trials. Recently, advances have been made in the development of analytical methods that are reliable and fast enough to allow determination of ADMA in clinical routine.

Keywords: coronary heart disease; endothelium; nitric oxide; prognosis; risk factors

References

  • 1.

    Kakimoto Y, Akazawa S. Isolation and identification of NG,NG- and NG,N′G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J Biol Chem 1970; 245:5751–8.Google Scholar

  • 2.

    McDermott JR. Studies on the catabolism of NG-methylarginine, NG,NG-dimethylarginine and NG,N′G-dimethyl-arginine in the rabbit. Biochem J 1976; 154:179–84.Google Scholar

  • 3.

    Böger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, et al. LDL cholesterol upregulates synthesis of asymmetric dimethylarginine (ADMA) in human endothelial cells. Involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87:99–105.CrossrefGoogle Scholar

  • 4.

    Böger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med 2003; 41:1467–72.CrossrefGoogle Scholar

  • 5.

    Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22–7.Google Scholar

  • 6.

    Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88:2149–55.CrossrefGoogle Scholar

  • 7.

    Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88:2510–6.CrossrefGoogle Scholar

  • 8.

    Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95:1119–21.CrossrefGoogle Scholar

  • 9.

    Böger RH, Bode-Böger SM, Szuba A, Tangphao O, Tsao PS, Chan JR, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98:1842–7.CrossrefGoogle Scholar

  • 10.

    Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102:994–9.CrossrefGoogle Scholar

  • 11.

    Böger RH, Bode-Böger SM, Frölich JC. The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis 1996; 127:1–11.Google Scholar

  • 12.

    Cooke JP. Asymmetrical dimethylarginine: the Über marker? Circulation 2004; 109:1813–8.CrossrefGoogle Scholar

  • 13.

    Böger RH. The emerging role of ADMA as a novel cardiovascular risk factor. Cardiovasc Res 2003; 59:824–33.CrossrefGoogle Scholar

  • 14.

    Ogawa T, Kimoto M, Sasaoka K. Occurrence of a new enzyme catalysing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun 1987; 148:671–7.Google Scholar

  • 15.

    Dayoub H, Achan V, Adimoolam S, Jacobi J, Stühlinger MC, Wang BY, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 2003; 108:3042–7.CrossrefGoogle Scholar

  • 16.

    MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119:1533–40.Google Scholar

  • 17.

    Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 1992; 339:572–5.Google Scholar

  • 18.

    Calver A, Collier J, Leone A, Moncada S, Vallance P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 1993; 7:193–4.Google Scholar

  • 19.

    Chan JR, Böger RH, Bode-Böger SM, Tangphao O, Tsao PS, Blaschke TF, et al. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol 2000; 20:1040–6.CrossrefGoogle Scholar

  • 20.

    Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolised by dimethylarginine dimethylaminohydolase. Arterioscler Thromb Vasc Biol 2003; 23:1455–9.CrossrefGoogle Scholar

  • 21.

    Kielstein JT, Impraim B, Simmel S, Bode-Böger SM, Tsikas D, Frölich JC, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109:172–7.CrossrefGoogle Scholar

  • 22.

    Böger RH, Lentz SR, Bode-Böger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci 2001; 100:161–7.CrossrefGoogle Scholar

  • 23.

    Sydow K, Schwedhelm E, Arakawa N, Bode-Böger SM, Tsikas D, Hornig B, et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia. Effects of L-arginine and B vitamins. Cardiovasc Res 2003; 57:244–52.CrossrefGoogle Scholar

  • 24.

    Sydow K, Hornig B, Arakawa N, Bode-Böger SM, Tsikas D, Münzel T, et al. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA. Vasc Med 2004; 9:1377–83.CrossrefGoogle Scholar

  • 25.

    Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia. Arterioscler Thromb Vasc Biol 2000; 20:1557–64.CrossrefGoogle Scholar

  • 26.

    Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway. Role of asymmetric dimethylarginine. Circulation 2001; 104:2569–75.CrossrefGoogle Scholar

  • 27.

    Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997, 95:2068–74.Google Scholar

  • 28.

    Surdacki A, Nowicki M, Sandmann J, Tsikas D, Böger RH, Bode-Böger SM, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33:652–8.CrossrefGoogle Scholar

  • 29.

    Kielstein JT, Böger RH, Bode-Böger SM, Schäffer J, Barbey M, Koch KM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10:594–600.Google Scholar

  • 30.

    Miyazaki H, Matsuoka H, Cooke JP. Endogenous nitric oxide synthase inhibitor. A novel marker of atherosclerosis. Circulation 1999; 99:1141–6.CrossrefGoogle Scholar

  • 31.

    Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino L, et al. Asymmetric dimethylarginine (ADMA), C-reactive protein, and carotid intima media-thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13:490–6.Google Scholar

  • 32.

    Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358:2127–8.Google Scholar

  • 33.

    Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino L, et al. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet 2001; 358:2113–7.Google Scholar

  • 34.

    Nijveldt RJ, Teerlink T, van der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003; 22:23–30.CrossrefGoogle Scholar

  • 35.

    Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003; 24:1912–9.CrossrefGoogle Scholar

  • 36.

    Krempl TK, Maas R, Sydow K, Meinertz T, Böger RH,Kähler J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 2005;28. In press.Google Scholar

  • 37.

    Bae SW, Stühlinger MC, Yoo HS, Yu KH, Park HK, Choi BY, et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 2005; 95:729–33.CrossrefGoogle Scholar

  • 38.

    Kielstein JT, Bode-Böger SM, Hesse G, Martens-Lobenhöffer J, Takacs A, Fliser D, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005; 25:1414–8.CrossrefGoogle Scholar

  • 39.

    Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24:1023–30.CrossrefGoogle Scholar

  • 40.

    Böger RH, Zoccali C. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atherosclerosis Suppl 2003; 4:23–8.CrossrefGoogle Scholar

  • 41.

    Kielstein JT, Böger RH, Bode-Böger SM, Martens-Lobenhöffer J, Lonnemann G, Frölich JC, et al. Low dialysance of asymmetric dimethylarginine (ADMA) – in vivo and in vitro evidence of significant protein binding. Clin Nephrol 2004; 62:295–300.CrossrefGoogle Scholar

  • 42.

    Schwedhelm E. Quantification of ADMA: analytical approaches. Vasc Med 2005. In press.CrossrefGoogle Scholar

  • 43.

    Albsmeier J, Schwedhelm E, Schulze F, Kastner M, Böger RH. Determination of NG,NG-dimethyl-L-arginine, an endogenous NO synthase inhibitor, by gas chromatography-mass spectrometry. J Chromatogr B 2004; 809:59–65.Google Scholar

  • 44.

    Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Böger RH. Liquid chromatography-tandem MS method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 2005; 51:1268–71.CrossrefGoogle Scholar

  • 45.

    Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, et al. Determination of ADMA using a novel ELISA assay. Clin Chem Lab Med 2004; 42:1377–83.CrossrefGoogle Scholar

  • 46.

    Böger RH. All about ADMA. www.allaboutadma.com (accessed May 09, 2005).Google Scholar

  • 47.

    Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307–10.Google Scholar

  • 48.

    NHLBI Framingham Heart Study. Estimating coronary heart disease (CHD) risk using Framingham Heart Study prediction score sheets, December 2002. http://www.nhlbi.nih.gov/about/framingham/riskabs.htm (accessed May 04, 2005).Google Scholar

  • 49.

    International Task Force for Prevention of Coronary Heart Disease. PROCAM risk calculator, 2004. http://www.chd-taskforce.de/calculator/calculator.htm (accessed May 04, 2005).Google Scholar

  • 50.

    European Society of Cardiology. CVD prevention score risk charts, 2004. http://www.escardio.org/initiatives/prevention/SCORE+Risk+Charts.htm (accessed May 04, 2005).Google Scholar

  • 51.

    Lee DS, Vasan RS. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 2005; 20:201–10.CrossrefGoogle Scholar

About the article

Corresponding author: Prof. Dr. med. Rainer H. Böger, Arbeitsgruppe Klinische Pharmakologie, Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany Phone: +40-42803-9759, Fax: +40-42803-9757,


Published Online: 2011-09-21

Published in Print: 2005-10-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 43, Issue 10, Pages 1124–1129, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2005.196.

Export Citation

©2005 by Walter de Gruyter Berlin New York.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Honglin Zhu, Weilin Chen, Di Liu, and Hui Luo
Metabolism, 2018
[2]
Rosa Vona, Antonello Giovannetti, Lucrezia Gambardella, Walter Malorni, Donatella Pietraforte, and Elisabetta Straface
Journal of Cellular and Molecular Medicine, 2018
[3]
Fatih Karaarslan, Kagan Ozkuk, Serap Seringec Karabulut, Seldag Bekpinar, Mufit Zeki Karagulle, and Nergis Erdogan
International Journal of Biometeorology, 2017
[4]
Arturo J. Cardounel, Hongmei Cui, Alexandre Samouilov, Wesley Johnson, Patrick Kearns, Ah-Lim Tsai, Vladomir Berka, and Jay L. Zweier
Journal of Biological Chemistry, 2007, Volume 282, Number 2, Page 879
[5]
Cabir Alan, Hasan Anil Kurt, Naci Topaloğlu, Ahmet Reşit Ersay, Dilek Ülker Çakir, and Gökhan Baştürk
International braz j urol, 2016, Volume 42, Number 3, Page 614
[6]
Scott L. Weiss, Min Yu, Lawrence Jennings, Shannon Haymond, Gang Zhang, Mark S. Wainwright, and Jorge Salluh
PLoS ONE, 2012, Volume 7, Number 3, Page e33355
[8]
Marc Breit and Klaus M. Weinberger
Archives of Biochemistry and Biophysics, 2016, Volume 589, Page 62
[9]
Bob Siegerink, Renke Maas, Carla Y. Vossen, Edzard Schwedhelm, Wolfgang Koenig, Rainer Böger, Dietrich Rothenbacher, Hermann Brenner, and Lutz P. Breitling
Clinical Research in Cardiology, 2013, Volume 102, Number 3, Page 193
[10]
Umit Inci, Abdulkadir Yildiz, Ibrahim Batmaz, and Ebru Tekbas
International Journal of Rheumatic Diseases, 2017, Volume 20, Number 2, Page 238
[11]
Wei Zhang, Jian Zhang, Yansheng Kang, Jingjing Liu, Xiaoqing Wang, Qingbin Xu, Yilei Wang, Xiaoya Xu, and Guidong Dai
European Journal of Pharmacology, 2014, Volume 745, Page 29
[12]
Dimitris Tousoulis, Chryssa Simopoulou, Nikos Papageorgiou, Evangelos Oikonomou, George Hatzis, Gerasimos Siasos, Eleftherios Tsiamis, and Christodoulos Stefanadis
Pharmacology & Therapeutics, 2014, Volume 144, Number 3, Page 253
[13]
Edyta Tenderenda-Banasiuk, Anna Wasilewska, Katarzyna Taranta-Janusz, and Agata Korzeniecka-Kozerska
Disease Markers, 2013, Volume 35, Page 407
[14]
Scott L. Weiss, Shannon Haymond, Hantamalala Ralay Ranaivo, Deli Wang, Victor R. De Jesus, Donald H. Chace, and Mark S. Wainwright
Pediatric Critical Care Medicine, 2012, Volume 13, Number 4, Page e210
[15]
Martina Huemer, Burkhard Simma, Dieter Mayr, Adolf Mühl, Birgit Rami, Edith Schober, Hanno Ulmer, Ulrike Zanier, and Olaf A. Bodamer
The Journal of Pediatrics, 2011, Volume 158, Number 4, Page 602
[16]
W. Schaper
European Heart Journal, 2012, Volume 33, Number 5, Page 564
[17]
M. Huemer, B. Simma, D. Mayr, D. Möslinger, A. Mühl, I. Schmid, H. Ulmer, and O.A. Bodamer
Journal of Inherited Metabolic Disease, 2012, Volume 35, Number 5, Page 817
[18]
F. Enseleit, I. Sudano, D. Periat, S. Winnik, M. Wolfrum, A. J. Flammer, G. M. Frohlich, P. Kaiser, A. Hirt, S. R. Haile, N. Krasniqi, C. M. Matter, K. Uhlenhut, P. Hogger, M. Neidhart, T. F. Luscher, F. Ruschitzka, and G. Noll
European Heart Journal, 2012, Volume 33, Number 13, Page 1589
[19]
Charles-Henry Cottart, Christelle Laguillier, Valérie Nivet-Antoine, Christophe Klimczak, Claude Sebban, and Jean-Louis Beaudeux
Comptes Rendus Biologies, 2009, Volume 332, Number 5, Page 433
[20]
Edzard Schwedhelm, Vanessa Xanthakis, Renke Maas, Lisa M. Sullivan, Dorothee Atzler, Nicole Lüneburg, Nicole L. Glazer, Ulrich Riederer, Ramachandran S. Vasan, and Rainer H. Böger
Clinical Chemistry and Laboratory Medicine, 2011, Volume 49, Number 11
[21]
Christina Charitidou, Dimitrios Farmakiotis, Vassiliki Zournatzi, Ifigenia Pidonia, Theodosia Pegiou, Nikolaos Karamanis, Maria Hatzistilianou, Ilias Katsikis, and Dimitrios Panidis
Atherosclerosis, 2008, Volume 196, Number 2, Page 958
[22]
David E.L. Wilcken, Ah Siew Sim, Jun Wang, and Xing Li Wang
Molecular Genetics and Metabolism, 2007, Volume 91, Number 4, Page 309
[23]
Vito De Gennaro Colonna, Sara Bonomo, Paolo Ferrario, Mauro Bianchi, Marco Berti, Marco Guazzi, Barbara Manfredi, Eugenio E. Muller, Ferruccio Berti, and Giuseppe Rossoni
European Journal of Pharmacology, 2007, Volume 557, Number 2-3, Page 178
[24]
Zeynep Soyman, Volkan Noyan, Murat Tulmac, Aykan Yucel, Nevin Sagsoz, Tulin Bayrak, Ahmet Bayrak, and Erdinc Cakir
Fertility and Sterility, 2011, Volume 95, Number 3, Page 1067
[25]
Jun-Lin Jiang, Shan Wang, Nian-Sheng Li, Xiao-Hong Zhang, Han-Wu Deng, and Yuan-Jian Li
Biochemistry and Cell Biology, 2007, Volume 85, Number 1, Page 66
[26]
George R. Thomas, Jonathan M. DiFabio, Tommaso Gori, David J.A. Jenkins, and John D. Parker
Canadian Journal of Physiology and Pharmacology, 2009, Volume 87, Number 6, Page 455
[27]
Grant V. Bochicchio and Thomas M. Scalea
Advances in Surgery, 2008, Volume 42, Page 261
[28]
Coen van Guldener, Prabath W.B. Nanayakkara, and Coen D.A. Stehouwer
Clinical Chemical Laboratory Medicine, 2007, Volume 45, Number 12
[29]
Ashit Syngle, Kanchan Vohra, Anjali Sharma, and L. Kaur
Clinical Rheumatology, 2010, Volume 29, Number 7, Page 763
[30]
G. Mossböck, M. Weger, A. Meinitzer, J. Semmelrock, O. Schmut, C. Faschinger, C. Zimmermann, W. Renner, and O. Stanger
Spektrum der Augenheilkunde, 2009, Volume 23, Number 5, Page 333
[31]
Ismail Sari, Levent Kebapcilar, Ahmet Alacacioglu, Oktay Bilgir, Yasar Yildiz, Ali Taylan, Arif Yuksel, and Didem L. Kozaci
Internal Medicine, 2009, Volume 48, Number 16, Page 1363
[32]
K. Schroecksnadel, G. Weiss, O. Stanger, T. Teerlink, and D. Fuchs
Scandinavian Journal of Immunology, 2007, Volume 65, Number 6, Page 525
[33]
Matthias Turina, Mirjam Christ-Crain, and Hiram C. Polk
Critical Care Medicine, 2006, Volume 34, Number Suppl, Page S291

Comments (0)

Please log in or register to comment.
Log in